- Home
- BLX vs TARS Comparison
BLX vs TARS Comparison
Compare BLX & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLX
- TARS
- Stock Information
- Founded
- BLX 1977
- TARS 2016
- Country
- BLX Panama
- TARS United States
- Employees
- BLX N/A
- TARS N/A
- Industry
- BLX Commercial Banks
- TARS Medicinal Chemicals and Botanical Products
- Sector
- BLX Finance
- TARS Health Care
- Exchange
- BLX Nasdaq
- TARS Nasdaq
- Market Cap
- BLX 1.6B
- TARS 1.7B
- IPO Year
- BLX N/A
- TARS 2020
- Fundamental
- Price
- BLX $45.71
- TARS $74.95
- Analyst Decision
- BLX
- TARS Strong Buy
- Analyst Count
- BLX 0
- TARS 7
- Target Price
- BLX N/A
- TARS $67.14
- AVG Volume (30 Days)
- BLX 116.7K
- TARS 652.5K
- Earning Date
- BLX 11-04-2025
- TARS 11-12-2025
- Dividend Yield
- BLX 5.47%
- TARS N/A
- EPS Growth
- BLX 12.91
- TARS N/A
- EPS
- BLX 5.97
- TARS N/A
- Revenue
- BLX $306,166,000.00
- TARS $295,521,000.00
- Revenue This Year
- BLX $18.52
- TARS $137.28
- Revenue Next Year
- BLX $5.81
- TARS $42.84
- P/E Ratio
- BLX $7.57
- TARS N/A
- Revenue Growth
- BLX 12.96
- TARS 254.45
- 52 Week Low
- BLX $31.14
- TARS $35.84
- 52 Week High
- BLX $48.38
- TARS $74.47
- Technical
- Relative Strength Index (RSI)
- BLX 51.35
- TARS 78.47
- Support Level
- BLX $44.15
- TARS $66.79
- Resistance Level
- BLX $45.68
- TARS $71.15
- Average True Range (ATR)
- BLX 0.81
- TARS 3.03
- MACD
- BLX -0.26
- TARS 0.97
- Stochastic Oscillator
- BLX 44.09
- TARS 99.64
About BLX Banco Latinoamericano de Comercio Exterior S.A.
Banco Latinoamericano de Comercio Exterior SA provides financial solutions to financial institutions, companies, and investors doing business in Latin America, supporting trade and regional integration. The Bank provides foreign trade solutions to a select client base of American financial institutions and corporations and has developed a network of correspondent banking institutions with access to the international capital markets. It has two business segments: the Commercial Business Segment and the Treasury Business Segment. The majority of its revenue is generated from the Commercial Business segment.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.